콘텐츠로 건너뛰기
Merck

Leflunomide in dermatology.

Journal of the American Academy of Dermatology (2011-10-04)
Alan S Boyd
초록

Leflunomide is an oral disease-modifying antirheumatic drug administered to patients with rheumatoid and psoriatic arthritis. This drug inhibits dihydroorotate dehydrogenase, an enzyme critical in the production of intracellular pyrimidines, and down-regulates tumor necrosis factor-alfa activity. Leflunomide has demonstrated usefulness in treating cutaneous psoriasis along with other dermatologic and rheumatologic conditions.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Leflunomide, Immunosuppressant
USP
Leflunomide, United States Pharmacopeia (USP) Reference Standard
Leflunomide for peak identification, European Pharmacopoeia (EP) Reference Standard
Leflunomide, European Pharmacopoeia (EP) Reference Standard
Supelco
Leflunomide, Pharmaceutical Secondary Standard; Certified Reference Material